Core Insights - Organogenesis Holdings Inc. commends the Centers for Medicare & Medicaid Services (CMS) for its payment reform for skin substitutes and cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule [1][2] Group 1: Payment Reform - The new payment methodology includes FDA classifications and a per centimeter square payment approach for both physician offices and hospital outpatient settings [2] - This reform is expected to enhance access to PMA products and address issues of abuse in the current payment system [2] Group 2: Company Positioning - Organogenesis believes it is well-positioned in the skin substitutes market for 2026 and beyond, leveraging over forty years of leadership in regenerative medicine [2] - The company has a diverse, evidence-based portfolio with technologies across all FDA categories, which supports its competitive stance in the market [2]